Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GH 
Guardant Health Inc (GH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: GH (1-star) is a SELL. SELL since 1 days. Simulated Profits (-6.45%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
24 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $61.95
1 Year Target Price $61.95
| 15 | Strong Buy |
| 6 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.24% | Avg. Invested days 25 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.85B USD | Price to earnings Ratio - | 1Y Target Price 61.95 |
Price to earnings Ratio - | 1Y Target Price 61.95 | ||
Volume (30-day avg) 24 | Beta 1.46 | 52 Weeks Range 20.14 - 68.00 | Updated Date 09/14/2025 |
52 Weeks Range 20.14 - 68.00 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.35 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -49.93% | Operating Margin (TTM) -45.75% |
Management Effectiveness
Return on Assets (TTM) -19.57% | Return on Equity (TTM) -4584.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7550736020 | Price to Sales(TTM) 8.26 |
Enterprise Value 7550736020 | Price to Sales(TTM) 8.26 | ||
Enterprise Value to Revenue 9.11 | Enterprise Value to EBITDA -5.4 | Shares Outstanding 124706000 | Shares Floating 119854799 |
Shares Outstanding 124706000 | Shares Floating 119854799 | ||
Percent Insiders 4.26 | Percent Institutions 99.11 |
Upturn AI SWOT
Guardant Health Inc
Company Overview
History and Background
Guardant Health Inc. was founded in 2012. It focuses on developing non-invasive cancer diagnostic tests using liquid biopsies. The company has grown from its initial focus on advanced cancer testing to include early cancer detection and minimal residual disease monitoring.
Core Business Areas
- Precision Oncology Testing: Offers comprehensive genomic profiling of tumors through liquid biopsies, primarily for advanced cancer patients. Guardant360 CDx is a key product.
- Early Cancer Detection: Developing tests for the early detection of cancer in asymptomatic individuals. Includes the ECLIPSE study assessing Shield, its blood-based colorectal cancer screening test.
- Development and Companion Diagnostics: Developing products for pharmaceutical clients to help them develop products for the precision oncology market.
Leadership and Structure
Helmy Eltoukhy (Co-Founder & CEO), AmirAli Talasaz (Co-Founder & Co-CEO). The company is structured with departments focusing on R&D, commercial operations, and clinical development.
Top Products and Market Share
Key Offerings
- Guardant360 CDx: A comprehensive genomic profiling test that analyzes circulating tumor DNA (ctDNA) in blood to identify actionable mutations in advanced cancer patients. Competitors include Foundation Medicine (FMI) and Qiagen. Market share estimates vary, but Guardant Health is a leading player in the liquid biopsy market. Revenue tied to this product is a significant portion of their diagnostics revenue.
- Guardant Reveal: A liquid biopsy test designed to detect minimal residual disease (MRD) after cancer treatment. Competitors include Natera (NTRA) and Adaptive Biotechnologies (ADPT). This product offers great market potential and is growing. Revenue is small but growing quickly as clinical adoption accelerates.
- Shield: A blood test for colorectal cancer screening currently being evaluated in the ECLIPSE study. Competitors in the broader cancer screening market include Exact Sciences (EXAS) with Cologuard. Still in development phase.
Market Dynamics
Industry Overview
The cancer diagnostics market is rapidly growing, driven by advances in genomics and personalized medicine. Liquid biopsies are gaining prominence as a non-invasive alternative to tissue biopsies.
Positioning
Guardant Health is a leader in the liquid biopsy market, particularly in advanced cancer genomic profiling. Its competitive advantages include its comprehensive genomic database, strong brand recognition, and established relationships with oncologists.
Total Addressable Market (TAM)
The total addressable market is estimated to be in the tens of billions of dollars across cancer screening, diagnosis, and monitoring. Guardant Health is positioned to capture a significant portion of this market through its innovative liquid biopsy technologies.
Upturn SWOT Analysis
Strengths
- Leading position in liquid biopsy market
- Comprehensive genomic database
- Strong brand recognition
- Established relationships with oncologists
- Innovative technology platform
Weaknesses
- High R&D costs
- Reliance on reimbursement approvals
- Intense competition
- Relatively low profit margins
- Early cancer detection tests still in development
Opportunities
- Expanding into early cancer detection
- Developing new liquid biopsy applications
- Partnering with pharmaceutical companies
- Increasing international presence
- Expanding use of AI and machine learning
Threats
- Competition from larger diagnostic companies
- Regulatory hurdles
- Reimbursement challenges
- Technological obsolescence
- Economic downturn
Competitors and Market Share
Key Competitors
- FMI
- NTRA
- EXAS
- ADPT
Competitive Landscape
Guardant Health's advantages include its comprehensive genomic database and established brand. Disadvantages include high R&D costs and reliance on reimbursement approvals. Foundation Medicine (FMI) offers the broadest FDA-approved panel; Natera (NTRA) offers the Signatera platform for minimal residual disease detection; Exact Sciences (EXAS) offers Cologuard for colorectal cancer screening, but it is stool-based.
Growth Trajectory and Initiatives
Historical Growth: Historically, Guardant Health has experienced strong revenue growth driven by increased adoption of its Guardant360 CDx test.
Future Projections: Future growth is expected to be driven by expansion into early cancer detection, MRD monitoring, and international markets. Analyst estimates vary widely, but generally anticipate continued revenue growth.
Recent Initiatives: Recent initiatives include the ongoing ECLIPSE study for its Shield colorectal cancer screening test, partnerships with pharmaceutical companies, and expansion of its commercial team.
Summary
Guardant Health is a leading liquid biopsy company with significant presence in advanced cancer genomic profiling. Its strength lies in established brand and database, but it needs to manage high R&D costs and competition. The success of its early cancer detection initiatives, such as Shield, will be crucial for future growth. Regulatory and reimbursement hurdles are factors to watch out for.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may vary. Future projections are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Guardant Health Inc
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2018-10-04 | Co-Founder, Co-CEO & Chairman Dr. Helmy Eltoukhy Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 1999 | Website https://guardanthealth.com |
Full time employees 1999 | Website https://guardanthealth.com | ||
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI blood test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and Smart Liquid Biopsy Platform. In addition, the company provides development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.